Skip to main content
News Gregor Hagelüken 08.2022
PD Dr. Gregor Hagelueken (left) Dr. Martin Peter (right)
© Johann Saba / UKB

News categories: Publication

Structure of periplasmic TRAP transporter revealed

Elevator Tripartite ATP-independent periplasmic (TRAP) transporter shows a monomeric elevator architecture

Elevator Tripartite ATP-independent periplasmic (TRAP) transporters are found among various bacteria and archaea. They are situated in the periplasmic space and act as transport proteins for organic acids and related molecules. Though TRAP transporters are known to harbor two transmembrane domains and one soluble substrate-binding protein domain, until now the exact molecular structure remained elusive. Scientists of the excellence cluster ImmunoSensation2 at the University of Bonn in cooperation with colleagues of the University of York have now identified the structure of the TRAP transporter HiSiaQM. A functional analysis further revealed potential target areas for transporter inhibition. The study has now been published in the journal Nature Communications.

TRAP transporters help pathogens such as Haemophilus influenzae or Vibrio cholerae to evade the immune system. Sialic acid, which is ubiquitous in human tissue, is taken up by the pathogens via TRAP transporters. Subsequently, the organic acid is incorporated into the bacterial cell wall. "There, it serves as a kind of invisibility cloak for the bacteria to hide from our immune system," says Bonn scientist PD Dr Gregor Hagelueken. The pathogens mimic the surface of endogenous cells, where sialic acid frequently occurs in the form of cell surface glycoproteins.

The researchers from Hagelueken's group at the Institute of Structural Biology of the University Hospital Bonn (UKB) used cryo-electron microscopy (cryoEM) to decipher the structure of the transporter. "Our results represent a real breakthrough, since attempts to decipher the structure of a TRAP transporter had already been going on for about 20 years," says post-doctoral researcher Martin Peter from Bonn. He recalls the moment when it became clear that the monumental task had been accomplished: "At that moment, we were the first to ever see a TRAP transporter. It was then immediately clear to us how the protein works. It moves up and down like an elevator in the membrane.”

In collaboration with Prof. Dr. Ulrich Kubitscheck's group at the Clausius Institute for Physical and Theoretical Chemistry at the University of Bonn, the researchers were able to watch the transporter at work in real time. "The TRAP transporter is found in many disease-causing bacteria," says Hagelueken. "Maybe in the future our structure can help develop antibiotics to make sure the elevator gets stuck." The scientists were also able to generate several single variable domains on heavy chain (VHH) antibodies, binding to the periplasmic side of the TRAP transporter with high affinity. Application of the VHHs effectively inhibited the uptake of sialic acid. These insights into the functional mechanisms of TRAP transporter might help designing inhibitors for therapeutical use in the future.


Publication

Martin F. Peter, Jan A. Ruland, Peer Depping, Niels Schneberger, Emmanuele Severi, Jonas Moecking, Karl Gatterdam, Sarah Tindall, Alexandre Durand, Veronika Heinz, Jan Peter Siebrasse, Paul-Albert Koenig, Matthias Geyer, Christine Ziegler, Ulrich Kubitscheck, Gavin H. Thomas & Gregor Hagelueken: Structural and mechanistic analysis of a tripartite ATP-independent periplasmic TRAP transporter; Nature Communications; https://www.nature.com/articles/s41467-022-31907-y


Contact

PD Dr. Gregor Hagelueken

Institute for Structural Biology

University Hospital Bonn

Phone: +49 228 287-51200

Email: hagelueken(at)uni-bonn.de

Related news

Dr. Ivana Jorgacevic und Prof. Dr. Rayk Behrendt have discovered that the inflammatory messenger substance interferon-alpha can trigger Sjögren's syndrome: The researchers in Bonn.

News categories: Publication

New test points to precision treatment for autoimmune condition

Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.
View entry
Precise Konsortium

News categories: Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry
Bild

News categories: Publication

Focus on the Guardians of the Antibody Response

For the immune system to effectively combat pathogens, antibody responses must be precisely controlled. So-called follicular regulatory T cells (Tfr cells) play a key role in this process by limiting excessive immune responses and helping to maintain immune tolerance. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now developed a robust laboratory method that allows Tfr cells to be generated from precursor cells and studied in a targeted manner. The results were recently published in the journal Cellular & Molecular Immunology.
View entry

Back to the news overview